$CPMV
Mosaic ImmunoEngineering Inc.

2023 Q3 Form 10-Q Financial Statement

#000168316823005245 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $226.9K $229.9K $581.0K
YoY Change -25.87% -60.44% 8.82%
% of Gross Profit
Research & Development $84.93K $122.6K $302.7K
YoY Change -59.77% -59.48% -19.66%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $311.9K $352.5K $883.7K
YoY Change -39.7% -60.11% -2.96%
Operating Profit -$311.9K -$352.5K -$883.7K
YoY Change -39.7% -60.11%
Interest Expense -$21.37K $16.12K -$43.50K
YoY Change -105.88% -137.06% -36.7%
% of Operating Profit
Other Income/Expense, Net -$21.38K $356.0K -$43.51K
YoY Change -105.88% -918.28% -36.69%
Pretax Income -$333.2K $19.61K -$927.2K
YoY Change 116.89% -102.11% -5.33%
Income Tax $0.00 $0.00 $2.400K
% Of Pretax Income 0.0%
Net Earnings -$333.2K $19.61K -$929.6K
YoY Change 116.88% -102.11% -5.08%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 $0.00 -$0.13
Diluted Earnings Per Share -$0.05 $0.00 -$0.13
COMMON SHARES
Basic Shares Outstanding 7.242M shares 7.242M shares 7.235M shares
Diluted Shares Outstanding 7.236M shares 8.569M shares 7.235M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $252.9K $363.0K $206.0K
YoY Change -34.16% 76.21% -64.62%
Cash & Equivalents $252.9K $363.0K $206.0K
Short-Term Investments
Other Short-Term Assets $32.63K $6.390K $17.16K
YoY Change -33.12% -62.76% -14.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $285.5K $369.4K $223.2K
YoY Change -34.05% 65.52% -62.95%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $285.5K $369.4K $223.2K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $285.5K $369.4K $223.2K
YoY Change -34.05% 65.52% -62.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $116.4K $131.1K $123.9K
YoY Change -4.01% 5.8% 79.24%
Accrued Expenses $649.2K $588.6K $1.191M
YoY Change 12.73% -50.6% 4.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.569M $4.346M $3.322M
YoY Change 26.99% 30.83% 122.49%
LONG-TERM LIABILITIES
Long-Term Debt $1.298M $1.276M $1.156M
YoY Change 8.84% 10.39% 85.58%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.298M $1.276M $1.156M
YoY Change 8.84% 10.39% 85.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.569M $4.346M $3.322M
Total Long-Term Liabilities $1.298M $1.276M $1.156M
Total Liabilities $5.867M $5.623M $4.478M
YoY Change 22.47% 25.55% 111.63%
SHAREHOLDERS EQUITY
Retained Earnings -$7.621M -$7.288M -$6.220M
YoY Change 19.56% 17.16%
Common Stock $72.00 $72.00 $72.00
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.581M -$5.253M -$4.255M
YoY Change
Total Liabilities & Shareholders Equity $285.5K $369.4K $223.2K
YoY Change -34.05% 65.52% -62.95%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$333.2K $19.61K -$929.6K
YoY Change 116.88% -102.11% -5.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$110.1K -$118.8K -$172.1K
YoY Change -33.23% -30.95% 12.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $356.0K $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $356.0K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -110.1K -118.8K -172.1K
Cash From Investing Activities 0.000 356.0K 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -110.1K 237.2K -172.1K
YoY Change -161.79% -237.85% -146.21%
FREE CASH FLOW
Cash From Operating Activities -$110.1K -$118.8K -$172.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000836564
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-22182
dei Entity Registrant Name
EntityRegistrantName
MOSAIC IMMUNOENGINEERING, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1070278
dei Entity Address Address Line1
EntityAddressAddressLine1
1537 South Novato Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
#5
dei Entity Address City Or Town
EntityAddressCityOrTown
Novato
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94947
dei City Area Code
CityAreaCode
657
dei Local Phone Number
LocalPhoneNumber
208-0890
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7242137 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362970 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
220645 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
6393 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
40632 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
369363 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261277 usd
CY2023Q2 us-gaap Assets
Assets
369363 usd
CY2022Q4 us-gaap Assets
Assets
261277 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
131076 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
133464 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
46700 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2826221 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2399132 usd
CY2023Q2 CPMV Accrued Consulting
AccruedConsulting
800590 usd
CY2022Q4 CPMV Accrued Consulting
AccruedConsulting
753570 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
588589 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
584808 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4346476 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3917674 usd
CY2023Q2 us-gaap Convertible Debt
ConvertibleDebt
1276199 usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
1228361 usd
CY2023Q2 us-gaap Liabilities
Liabilities
5622675 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5146035 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2034148 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2023271 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7287533 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6908102 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884758 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
369363 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261277 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122638 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
302694 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
300533 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
630353 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
229868 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
581032 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
511746 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
982409 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
352506 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
883726 usd
us-gaap Operating Expenses
OperatingExpenses
812279 usd
us-gaap Operating Expenses
OperatingExpenses
1612762 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-352506 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-883726 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-812279 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1612762 usd
CY2023Q2 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
356000 usd
CY2022Q2 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
3378 usd
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
7 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3386 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
14 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
33900 usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
800 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46700 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1300 usd
CY2023Q2 us-gaap Noninterest Expense
NoninterestExpense
18283 usd
CY2022Q2 us-gaap Noninterest Expense
NoninterestExpense
18282 usd
us-gaap Noninterest Expense
NoninterestExpense
36365 usd
us-gaap Noninterest Expense
NoninterestExpense
32770 usd
CY2023Q2 us-gaap Accretion Expense
AccretionExpense
2877 usd
CY2022Q2 us-gaap Accretion Expense
AccretionExpense
26031 usd
us-gaap Accretion Expense
AccretionExpense
11473 usd
us-gaap Accretion Expense
AccretionExpense
46498 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
372118 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43506 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
435248 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77954 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19612 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-927232 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-377031 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1690716 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19612 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-929632 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
us-gaap Net Income Loss
NetIncomeLoss
-1693116 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7235447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7235447 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8569113 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7235447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7235447 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5278393 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5469 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19612 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3423490 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
97997 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-929632 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4255125 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884758 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10877 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2799011 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
237002 usd
us-gaap Net Income Loss
NetIncomeLoss
-1693116 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4255125 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
us-gaap Net Income Loss
NetIncomeLoss
-1693116 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
-0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10877 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
237002 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46700 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1300 usd
us-gaap Noninterest Expense
NoninterestExpense
36365 usd
us-gaap Noninterest Expense
NoninterestExpense
32770 usd
us-gaap Accretion Expense
AccretionExpense
11473 usd
us-gaap Accretion Expense
AccretionExpense
46498 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34239 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-26195 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-2388 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
10376 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
427089 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
512638 usd
CPMV Increase Decrease In Accrued Consulting
IncreaseDecreaseInAccruedConsulting
47020 usd
CPMV Increase Decrease In Accrued Consulting
IncreaseDecreaseInAccruedConsulting
193463 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3781 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
273694 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-290675 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-361780 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
433000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
341632 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
341632 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
142325 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20148 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220645 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226142 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362970 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205994 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_805_eus-gaap--NatureOfOperations_zPTHNyOYtg2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt"><b>1. <span id="xdx_82B_ziQZHVuRUyMb">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing our proprietary immunotherapy platform technology. Our lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in humans and animals. However, because of its virus structure and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral (“IT”) administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-101 is currently in late-stage preclinical development and our goal is to advance MIE-101 into veterinary studies and into Phase I clinical trials within 18 to 24 months from the date we are able to raise sufficient funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At June 30, 2023, the Company had cash and cash equivalents of $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20230630_pp0p0" title="Cash and cash equivalents">362,970</span> and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations and may require us to cease our operations altogether. In addition, any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362970 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpyikod6C25h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zAlOUvoF7yhj">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to amounts in the prior period to conform to the current period presentation. All reclassifications have been applied consistently to the periods presented. Such reclassifications have no effect on net loss as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
362970 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
220645 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
46700 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
46700 usd
CY2023Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
177244 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
177244 usd
CY2023Q2 CPMV Accrued Patent Expenses
AccruedPatentExpenses
408585 usd
CY2022Q4 CPMV Accrued Patent Expenses
AccruedPatentExpenses
382207 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2760 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25357 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
588589 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
584808 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
916632 usd
CY2023Q2 CPMV Convertible Notes Redemption Value
ConvertibleNotesRedemptionValue
1145790 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5469 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
97997 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10877 usd
us-gaap Share Based Compensation
ShareBasedCompensation
237002 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2023Q2 CPMV Accrued Consulting Fees
AccruedConsultingFees
276625 usd
CY2022Q4 CPMV Accrued Consulting Fees
AccruedConsultingFees
238000 usd

Files In Submission

Name View Source Status
0001683168-23-005245-index-headers.html Edgar Link pending
0001683168-23-005245-index.html Edgar Link pending
0001683168-23-005245.txt Edgar Link pending
0001683168-23-005245-xbrl.zip Edgar Link pending
cpmv-20230630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mosaic_ex3101.htm Edgar Link pending
mosaic_ex3102.htm Edgar Link pending
mosaic_ex3201.htm Edgar Link pending
mosaic_ex3202.htm Edgar Link pending
mosaic_i10q-063023.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
cpmv-20230630_cal.xml Edgar Link unprocessable
cpmv-20230630_def.xml Edgar Link unprocessable
cpmv-20230630_lab.xml Edgar Link unprocessable
mosaic_i10q-063023_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cpmv-20230630_pre.xml Edgar Link unprocessable